Clinical trials for Clear cell renal carcinoma
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center · PI: Sumanta K Pal
- RECRUITINGPhase 2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie · PI: Karie Runcie, MD
- RECRUITINGPhase 2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute · PI: Wenxin Xu, MD
- RECRUITINGPhase 2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini · PI: Brian Rini, MD
- RECRUITINGPhase 2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPhase 2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma · PI: Adanma Ayanambakkam, MD
- RECRUITINGPhase 1NCT07300241Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaNeomorph, Inc · PI: Klaus Wagner, MD, PhD
- RECRUITINGPhase 2NCT07187778Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)M.D. Anderson Cancer Center · PI: Eric Jonasch, MD
- RECRUITINGPhase 2NCT07123090A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaStephanie Berg · PI: Stephanie Berg, DO
- RECRUITINGPhase 2NCT07389629Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCSun Yat-sen University
- RECRUITINGPhase 3NCT07197580Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCCTelix Pharmaceuticals (Innovations) Pty Limited
- RECRUITINGNCT07240610Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell CarcinomaZhe Chen · PI: Hiroshi Onishi, MD, PhD
- ENROLLING BY INVITATIONPhase 2NCT07488572Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical StudySun Yat-sen University
- RECRUITINGPhase 2NCT06794229Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisQian Qin · PI: Qian Qin, MD
- RECRUITINGNCT07234656Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney CancerBrigitta Rasmussen Villumsen · PI: Brigitta R Villumsen, PhD
- RECRUITINGPhase 1NCT07072234Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell CarcinomaM.D. Anderson Cancer Center · PI: Andrew C Johns, MD
- RECRUITINGPhase 1NCT07179770Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)NYU Langone Health · PI: Minas Economides, MD
- RECRUITINGPhase 3NCT07011719Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaArcus Biosciences, Inc. · PI: Medical Director
- RECRUITINGPHASE1, PHASE2NCT06866262Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialUniversity of Michigan Rogel Cancer Center · PI: Ulka N Vaishampayan
- ACTIVE NOT RECRUITINGPhase 2NCT07488533Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell CarcinomaSun Yat-sen University
- ACTIVE NOT RECRUITINGPhase 2NCT06964958177LuPSMA in Renal Cell CarcinomaDana-Farber Cancer Institute · PI: Praful Ravi, MB BCHir, MRCP
- ACTIVE NOT RECRUITINGPhase 3NCT07000149A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPHASE1, PHASE2NCT07097935Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell CarcinomaJiangsu Hansoh Pharmaceutical Co., Ltd.
- RECRUITINGPhase 1NCT06942104Imaging of Solid Tumors Using 18F-TRXRahul Aggarwal · PI: Rahul Aggarwal, MD
- RECRUITINGPhase 2NCT06940518Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell CarcinomaM.D. Anderson Cancer Center · PI: Pavlos Msaouel, MD
- RECRUITINGPhase 3NCT06661720Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE1, PHASE2NCT06835972A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)Memorial Sloan Kettering Cancer Center · PI: Martin Voss, MD
- RECRUITINGPhase 2NCT06699602A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaMemorial Sloan Kettering Cancer Center · PI: Martin Voss, MD
- RECRUITINGN/ANCT06852638CD70-targeted immunoPET Imaging of Malignant CancersRenJi Hospital · PI: Jianjun Liu, Ph.D. & M.D.
- RECRUITINGPhase 1NCT06819293IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell CarcinomaGrit Biotechnology
- RECRUITINGPhase 2NCT06680089CD70-targeted immunoPET Imaging of Kidney CancerRenJi Hospital · PI: Wei Zhai, Ph.D. & M.D.
- ACTIVE NOT RECRUITINGN/ANCT06453642Evaluation of a Simple-Prep Controlled EmbolicFluidx Medical Technology, Inc. · PI: Michael Darcy, MD
- RECRUITINGPhase 3NCT0675041989Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyTelix Pharmaceuticals (Innovations) Pty Limited
- RECRUITINGNCT06863857Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal CancerIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Francesco Massari, MD
- RECRUITINGPHASE1, PHASE2NCT06413680A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyRegeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGNCT06676527Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell CarcinomaJinling Hospital, China · PI: Yuxiu Liu, M. D.
- RECRUITINGPhase 2NCT06447103An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney CancerJonsson Comprehensive Cancer Center · PI: Brian Shuch
- ACTIVE NOT RECRUITINGNCT07332923Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine LearningFirst Affiliated Hospital of Fujian Medical University
- RECRUITINGN/ANCT06536439Planning Operative Strategy Using a Digital Renal Artery Clamping ToolUniversity Hospital, Ghent · PI: Charles Van Praet, MD, PhD
- RECRUITINGPhase 2NCT06690697Combination of Toripalimab and JS004 Therapy for ccRCCFudan University
- RECRUITINGPhase 1NCT06234605A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell CarcinomaHiberCell, Inc.
- RECRUITINGNCT06349642Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformMayo Clinic · PI: Dev Mukhopadhyay, PhD
- RECRUITINGPhase 2NCT0661326968Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.Peking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06245915AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)Arsenal Biosciences, Inc. · PI: Arsenal Biosciences
- RECRUITINGPhase 2NCT06211790Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaFudan University
- RECRUITINGPhase 2NCT06053658Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaM.D. Anderson Cancer Center · PI: Eric Jonasch, M D
- RECRUITINGPhase 2NCT04974671Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell CarcinomaYale University · PI: Kimberly Johung, MD
- RECRUITINGNCT06195150Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal CancerIRCCS San Raffaele
- RECRUITINGPhase 2NCT06004336A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)M.D. Anderson Cancer Center · PI: Chad Tang, MD
- ACTIVE NOT RECRUITINGPhase 1NCT06049576Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaCity of Hope Medical Center · PI: Sumanta K Pal
- RECRUITINGN/ANCT06035211Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery- Rein 3D AnxietyUniversity Hospital, Bordeaux · PI: Jean-Christophe BERNHARD, Professeur
- RECRUITINGPhase 2NCT06035224A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell CarcinomaRenJi Hospital
- RECRUITINGPhase 2NCT05127824Autologous Dendritic Cell Vaccine in Kidney CancerJodi Maranchie · PI: Jodi Maranchie, MD
- RECRUITINGN/ANCT05753839The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN TrialYonsei University · PI: Won Sik Ham
- RECRUITINGPHASE1, PHASE2NCT05663710Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCM.D. Anderson Cancer Center · PI: Eric Jonasch, MD
- RECRUITINGPhase 2NCT05831891Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell CarcinomaRenJi Hospital
- RECRUITINGPHASE1, PHASE2NCT05706129A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsITM Oncologics GmbH
- ACTIVE NOT RECRUITINGNCT05782400Multiomics Approach in Metastatic Clear Renal Cell CarcnomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano · PI: Giuseppe Procopio, MD
- RECRUITINGEarly Phase 1NCT05188118Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell CarcinomaIcahn School of Medicine at Mount Sinai · PI: Che-Kai Tsao
- RECRUITINGPhase 2NCT05768464Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · PI: hongqian guo
- ACTIVE NOT RECRUITINGPhase 3NCT05219318Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase InhibitorsUniversity Hospital, Bordeaux · PI: Marine GROSS-GOUPIL, MD PhD
- ACTIVE NOT RECRUITINGPhase 3NCT05678673Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaExelixis
- RECRUITINGNCT05917106Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)Jinling Hospital, China
- RECRUITINGNCT05548621A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)St. Antonius Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05363631Seleno-L Methionine (SLM)-Axitinib-PembrolizumabMohammed Milhem · PI: Mohammed Milhem, MD
- RECRUITINGPhase 2NCT05155033Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaNational Cancer Institute (NCI) · PI: Stephanie L Goff, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05148546Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerThe Netherlands Cancer Institute · PI: John Haanen, Prof
- ACTIVE NOT RECRUITINGPhase 2NCT05239533Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerMemorial Sloan Kettering Cancer Center · PI: Darren Feldman, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05012371Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerM.D. Anderson Cancer Center · PI: Andrew W Hahn, MD
- RECRUITINGNCT05214885Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell CarcinomaQianfoshan Hospital · PI: Li Zhang, Dr.
- RECRUITINGPhase 2NCT05024318NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell CarcinomaPeter MacCallum Cancer Centre, Australia · PI: Shankar Siva, A/Prof
- RECRUITINGPhase 1NCT07062549Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal CellSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PI: Yasser Ged, MBBS
- RECRUITINGEarly Phase 1NCT06428708[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell CarcinomaWestern University · PI: Melissa Huynh, MD
- RECRUITINGPhase 1NCT05176483Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsExelixis · PI: Medical Director
- RECRUITINGPHASE1, PHASE2NCT05086692A Beta-only IL-2 ImmunoTherapY StudyMedicenna Therapeutics, Inc. · PI: Nina Merchant
- RECRUITINGPhase 1NCT04989959[18F]PT2385 PET/CT in Patients With Renal Cell CarcinomaOrhan Kemal Oz · PI: James Brugarolas, MD, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT04810078A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadBristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 3NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Merck Sharp & Dohme LLC · PI: Medical Director
- ACTIVE NOT RECRUITINGNCT06898632KidneyCare Cohort Study (KCC-S)University of Utah · PI: Alejandro Sanchez, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04696731Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaAllogene Therapeutics
- ACTIVE NOT RECRUITINGPhase 1NCT04388852DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersM.D. Anderson Cancer Center · PI: Ana Aparicio
- ACTIVE NOT RECRUITINGPhase 2NCT04645680Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving ImmunotherapyM.D. Anderson Cancer Center · PI: Erez Baruch, MD,PHD
- ACTIVE NOT RECRUITINGPhase 2NCT04393350Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaEmory University · PI: Mehmet A Bilen, MD
- RECRUITINGNCT04053855Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell CarcinomaCentre Hospitalier Universitaire de Saint Etienne · PI: Nicolas MOTTET, MD PhD
- RECRUITINGPHASE1, PHASE2NCT03972657A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsRegeneron Pharmaceuticals · PI: Clinical Trials Management
- ACTIVE NOT RECRUITINGPhase 2NCT04022343Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney CancerEmory University · PI: Mehmet Asim Bilen, MD
- ACTIVE NOT RECRUITINGPhase 3NCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyNational Cancer Institute (NCI) · PI: Tian Zhang
- ACTIVE NOT RECRUITINGPhase 1NCT02950766NeoVax Plus Ipilimumab in Renal Cell CarcinomaPatrick Ott, MD, PhD · PI: Patrick Ott, MD
- RECRUITINGNCT03414827Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell CarcinomaZealand University Hospital
- ACTIVE NOT RECRUITINGPhase 2NCT03682289Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsRahul Aggarwal · PI: Rahul Aggarwal, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03634540A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · PI: Medical Director
- ACTIVE NOT RECRUITINGPhase 1NCT03354390HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell CarcinomaNational Heart, Lung, and Blood Institute (NHLBI) · PI: Richard W Childs, M.D.
- RECRUITINGPhase 3NCT03592472A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Xynomic Pharmaceuticals, Inc. · PI: Pamela Munster, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03294083A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaSillaJen, Inc.
- ACTIVE NOT RECRUITINGPhase 2NCT03501381High Dose IL 2 and Entinostat in RCCRoberto Pili · PI: Roberto Pili, MD
- ACTIVE NOT RECRUITINGNCT03455452Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerBristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03308396Study of Durvalumab and Guadecitabine in Advanced Kidney CancerAjjai Alva, MD · PI: Ajjai Alva, M.D.